Current stage-Stage III Posts on Medivizor
Navigation Menu

Current stage-Stage III Posts on Medivizor

Is gefitinib beneficial when combined with chemotherapy in the treatment of non-small cell lung cancer?

Is gefitinib beneficial when combined with chemotherapy in the treatment of non-small cell lung cancer?

Posted by on Sep 8, 2020 in Lung cancer | 0 comments

In a nutshell This article looked at the effectiveness of gefitinib (Iressa) combined with chemotherapy when compared to a chemotherapy aline in the treatment of non-small cell lung cancer (NSCLC). The authors found that the addition of gefitinib to a chemotherapy increased the progression-free survival (PFS) of these...

Read More

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Searching for patients with advanced triple-negative breast cancer to trial a treatment combination

Posted by on Sep 6, 2020 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...

Read More

Searching for patients with stage III non-small cell lung cancer to trial a biological treatment.

Searching for patients with stage III non-small cell lung cancer to trial a biological treatment.

Posted by on Sep 6, 2020 in Lung cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....

Read More

Does chemotherapy after complete removal of rectal cancer improve outcomes?

Does chemotherapy after complete removal of rectal cancer improve outcomes?

Posted by on Aug 30, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the differences in following the guidelines for advanced rectal cancer treatments. Researchers suggested chemotherapy after the complete removal of rectal cancer improves survival. Some background This year, an estimated 147,950 adults in the US will be diagnosed with colorectal cancer. Of these, 43,340 will be...

Read More

Looking for patients with stage III non-small cell lung cancer to trial a treatment combination with radiotherapy

Looking for patients with stage III non-small cell lung cancer to trial a treatment combination with radiotherapy

Posted by on Aug 23, 2020 in Lung cancer | 0 comments

In a nutshell This study is looking to examine the effectiveness of durvalumab (Imfinzi) and consolidation stereotactic body radiation therapy (SBRT) after chemoradiation for locally advanced stage III non-small-cell lung cancer (NSCLC). The main outcomes to be measured are the occurrence of side effects and the survival without cancer...

Read More

Searching for patients with advanced breast cancer to trial an experimental drug combination

Searching for patients with advanced breast cancer to trial an experimental drug combination

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...

Read More

Evaluating immune-related side effets in patients with advanced melanoma treated with immunotherapies

Evaluating immune-related side effets in patients with advanced melanoma treated with immunotherapies

Posted by on Jun 28, 2020 in Melanoma | 0 comments

In a nutshell The study monitored the occurrence of possible immune-related side effects (irSEs) in patients with advanced melanoma under single and combination therapy of ipilimumab (I; Yervoy), nivolumab (N; Opdivo), and pembrolizumab (P; Keytruda). The authors found that combination therapy increases the frequency of irSEs. Some background...

Read More

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Posted by on Jun 28, 2020 in Breast cancer | 0 comments

In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...

Read More

S1-based chemotherapy improves the outcomes of patients with advanced colorectal cancer

S1-based chemotherapy improves the outcomes of patients with advanced colorectal cancer

Posted by on Jun 25, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of two different chemotherapies in the treatment of advanced colorectal cancer (CRC). Researchers suggested that S1-based chemotherapy is a good option for the treatment of these patients. Some background CRC is one of the most common cancers worldwide. The standard treatment is surgery...

Read More

Can specialized imaging techniques improve how chemo-radiotherapy is administered in locally advanced non-small cell lung cancer?

Posted by on Apr 21, 2020 in Lung cancer | 0 comments

In a nutshell This study set out to compare conventional-dose chemoradiotherapy (CRT) to reduced CRT based on 18F-FDG PET in locally advanced non-small cell lung cancer (NSCLC). The investigators found that 18F-FDG PET-based CRT improved tumor control without increasing side effects in these patients.  Some background NSCLC accounts for...

Read More